Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6425
    -0.0000 (-0.01%)
     

  • OIL

    82.76
    +0.03 (+0.04%)
     

  • GOLD

    2,396.40
    -1.60 (-0.07%)
     

  • Bitcoin AUD

    101,183.95
    +3,582.20 (+3.67%)
     

  • CMC Crypto 200

    1,383.21
    +70.59 (+5.69%)
     

  • AUD/EUR

    0.6020
    -0.0011 (-0.18%)
     

  • AUD/NZD

    1.0891
    +0.0016 (+0.15%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,299.92
    -94.39 (-0.54%)
     

  • FTSE

    7,853.75
    -23.30 (-0.30%)
     

  • Dow Jones

    37,974.64
    +199.26 (+0.53%)
     

  • DAX

    17,758.30
    -79.10 (-0.44%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Soleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Soleno Therapeutics
·1-min read

REDWOOD CITY, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 2:40 PM Eastern Time.

A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.soleno.life.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578